

Cover Story
Free
By Matthew Bin Han Ong
Update: The New England Journal of Medicine's subsequent response after this article is published is appended at the end.
In Brief


Drugs & Targets
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- In The Headlines: Private funding can’t replace federal funding—but it can help
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed